Suppr超能文献

保护心脏免受缺血再灌注损伤的新方向:靶向再灌注损伤挽救激酶(RISK)通路。

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.

作者信息

Hausenloy Derek J, Yellon Derek M

机构信息

The Hatter Institute and Centre for Cardiology, University College London Hospital and Medical School, Grafton Way, London WC1E 6DB, UK.

出版信息

Cardiovasc Res. 2004 Feb 15;61(3):448-60. doi: 10.1016/j.cardiores.2003.09.024.

Abstract

Reperfusion is a pre-requisite to salvaging viable myocardium, following an acute myocardial infarction. Reperfusion of ischaemic myocardium, however, is not without risk, as the act of reperfusion itself can paradoxically result in myocyte death: a phenomenon termed lethal reperfusion-induced injury. Therapeutic strategies that target and attenuate reperfusion-induced cell death may provide novel pharmacological agents, which can be used as an adjunct to current reperfusion therapy, to limit myocardial infarction. Recent evidence has implicated apoptotic cell death during the phase of reperfusion as an important contributor to lethal reperfusion-induced injury. Targeting anti-apoptotic mechanisms of cellular protection at the time of reperfusion may therefore offer a potential approach to attenuating reperfusion-induced cell death. In this regard, ischaemia-reperfusion has been shown to activate the anti-apoptotic pro-survival kinase signalling cascades, phosphatidylinositol-3-OH kinase (PI3K)-Akt and p42/p44 extra-cellular signal-regulated kinases (Erk 1/2), both of which have been implicated in cellular survival. Activating these pro-survival kinase cascades at the time of reperfusion has been demonstrated to confer protection against reperfusion-induced injury. We and others have shown that insulin, insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1), cardiotrophin-1 (CT-1), urocortin, atorvastatin and bradykinin protect the heart, by activating the PI3K-Akt and/or Erk 1/2 kinase cascades, when given at the commencement of reperfusion, following a lethal ischaemic insult. Pharmacological manipulation and up-regulation of these pro-survival kinase cascades, which we refer to as the Reperfusion Injury Salvage Kinase (RISK) pathway, as an adjunct to reperfusion may therefore protect the myocardium from lethal reperfusion-induced cell death and provide a novel strategy to salvaging viable myocardium and limiting infarct size.

摘要

再灌注是急性心肌梗死后挽救存活心肌的一个先决条件。然而,缺血心肌的再灌注并非没有风险,因为再灌注本身的行为可能反常地导致心肌细胞死亡:这一现象被称为致死性再灌注诱导损伤。针对并减轻再灌注诱导的细胞死亡的治疗策略可能会提供新的药物制剂,这些制剂可作为当前再灌注治疗的辅助手段,以限制心肌梗死。最近的证据表明,再灌注阶段的凋亡性细胞死亡是致死性再灌注诱导损伤的一个重要促成因素。因此,在再灌注时靶向细胞保护的抗凋亡机制可能提供一种减轻再灌注诱导的细胞死亡的潜在方法。在这方面,缺血再灌注已被证明可激活抗凋亡的促存活激酶信号级联反应,即磷脂酰肌醇-3-羟基激酶(PI3K)-Akt和p42/p44细胞外信号调节激酶(Erk 1/2),这两者都与细胞存活有关。已证明在再灌注时激活这些促存活激酶级联反应可赋予对再灌注诱导损伤的保护作用。我们和其他人已经表明,胰岛素、胰岛素样生长因子-1(IGF-1)、转化生长因子-β1(TGF-β1)、心肌营养素-1(CT-1)、尿皮质素、阿托伐他汀和缓激肽在致死性缺血损伤后的再灌注开始时给予,可通过激活PI3K-Akt和/或Erk 1/2激酶级联反应来保护心脏。因此,作为再灌注的辅助手段,对这些促存活激酶级联反应进行药理学操纵和上调,我们称之为再灌注损伤挽救激酶(RISK)途径,可能保护心肌免受致死性再灌注诱导的细胞死亡,并提供一种挽救存活心肌和限制梗死面积的新策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验